Procter&Gamble Healt
Ticker > Company >

Procter&Gamble Healt share price

Procter & Gamble Health Ltd.

NSE: PGHL BSE: 500126 SECTOR: Pharmaceuticals & Drugs  1.14 L   380   40

6245.35
-10.90 (-0.17%)
BSE: 12 Sep 04:01 PM

Price Summary

Today's High

₹ 6348

Today's Low

₹ 6226.55

52 Week High

₹ 6700

52 Week Low

₹ 4912.3

FinStar

Ownership Stable
Ownership strength is slightly missing the benchmark.
ValuationExpensive
The stock is at a premium valuation at this point.
EfficiencyExcellent
The company knows very well the utilization of its assets.
FinancialsWeak
Watch out! The company might not be able to sustain any adverse condition.
*It is just an analytical rating of the company and not an investment advice.

Company Essentials

Market Cap

₹ 10366.9 Cr.

Enterprise Value

₹ 10178.35 Cr.

No. of Shares

1.66 Cr.

P/E

34.49

P/B

17.33

Face Value

₹ 10

Div. Yield

2 %

Book Value (TTM)

₹  360.4

CASH

₹ 188.55 Cr.

DEBT

₹ 0 Cr.

Promoter Holding

51.82 %

EPS (TTM)

₹  181.09

Sales Growth

-18.86%

ROE

44.15 %

ROCE

58.05%

Profit Growth

16.63 %

Add Your Ratio

* Total debt includes long term borrowing, short term borrowing plus current maturities of long-term borrowing
* Ratios are based on latest Audited Financial Result.

Your Added Ratios

Please login to Add & View your own added ratios.

Login

Brands

These are the brands of Procter & Gamble Health Ltd.

Seven seas evion nasvision Polybion Livogen Neurobion

Price Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

 

Volume Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

* Prices are based on daily market changes.

PE Chart 1w 1m 3m 6m 1Yr 3Yr 5Yr

PB Chart 1w 1m 3m 6m 1Yr 3Yr 5Yr

* The chart is based on the standalone earnings of the company. * Negative values and values more than 1000x in PE chart is considered 0.

Peer Comparison

View Full Peer Comparison
* The Peers list includes companies operating in the same industry and having comparable market cap.

 Group Companies

Track the companies of Group.

Ratios

Sales Growth

1 Year-18.86%
3 Year-8.75%
5 Year-1.52%

Profit Growth

1 Year16.63%
3 Year0.71%
5 Year5.8%

ROE%

1 Year44.15%
3 Year35.77%
5 Year34.13%

ROCE %

1 Year58.05%
3 Year47.69%
5 Year45.52%

Debt/Equity

0

Price to Cash Flow

61.46

Interest Cover Ratio

725.6977

CFO/PAT (5 Yr. Avg.)

0.97395971125137

Shareholding Pattern

Promoter Pledging %

Date Promoter % Pledge %
Jun 2025 51.82 0.00
Mar 2025 51.82 0.00
Dec 2024 51.82 0.00
Sep 2024 51.82 0.00
Jun 2024 51.82 0.00
Investors List
* Figures given above are % of equity capital

 Strengths

  • Company has been maintaining healthy ROE of 35.7726% over the past 3 years.
  • Company has been maintaining healthy ROCE of 47.692% over the past 3 years.
  • Company is virtually debt free.
  • Company has a healthy Interest coverage ratio of 725.6977.
  • The Company has been maintaining an effective average operating margins of 25.3422293065272% in the last 5 years.
  • The company has an efficient Cash Conversion Cycle of -155.7427 days.
  • Company has a healthy liquidity position with current ratio of 2.4448.
  • The company has a high promoter holding of 51.82%.

 Limitations

  • The company has shown a poor profit growth of 0.712506900865817% for the Past 3 years.
  • The company has shown a poor revenue growth of -8.75297149062362% for the Past 3 years.
  • Company has contingent liabilities of 182.29 Cr.

Quarterly Result (All Figures in Cr.)

PARTICULARS Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025
Net Sales 283.88 313.41 309.77 310.99 338.74
Total Expenditure 235.63 199.37 186.34 230.07 248.4
Operating Profit 48.25 114.04 123.43 80.92 90.34
Other Income 2.13 3.28 3.96 3.11 4.03
Interest 0.2 0.15 0.15 0.13 0.12
Depreciation 7.16 5.77 5.55 5.37 5.44
Exceptional Items -20.19 0 0 0 0
Profit Before Tax 22.83 111.4 121.69 78.53 88.81
Tax 6.05 29.07 30.79 17.35 22.63
Profit After Tax 16.78 82.33 90.9 61.18 66.18
Adjusted EPS (Rs) 10.11 49.6 54.76 36.86 39.87

Profit & Loss (All Figures in Cr. Adjusted EPS in Rs.)

PARTICULARS Jun 2022 Jun 2023 Mar 2024 Jun 2024 Mar 2025
Net Sales 1114.41 1229.62 1151.26 1151.26 934.17
Total Expenditure 846.73 904.94 845.26 845.26 615.78
Operating Profit 267.68 324.68 306 306 318.39
Other Income 13.19 18.39 15.63 15.63 10.35
Interest 0.42 0.77 0.72 0.72 0.43
Depreciation 27.08 28.1 27.4 27.4 16.69
Exceptional Items 0 0 -20.19 -20.19 0
Profit Before Tax 253.37 314.2 273.32 273.32 311.62
Tax 60.85 84.73 72.34 72.34 77.21
Net Profit 192.52 229.47 200.98 200.98 234.41
Adjusted EPS (Rs.) 115.98 138.23 121.07 121.07 141.21

Balance Sheet (All Figures are in Crores.)

Particulars Jun 2022 Jun 2023 Mar 2024 Jun 2024 Mar 2025
Equity and Liabilities
Share Capital 16.6 16.6 16.6 16.6 16.6
Total Reserves 599.89 734.29 521.64 521.64 520.36
Borrowings 0 0 0 0 0
Other N/C liabilities 713.63 803 3.52 840.55 6.87
Current liabilities 607.73 679.08 218.91 625.3 215.31
Total Liabilities 1937.85 2232.97 760.67 2004.09 759.14
Assets
Net Block 109.06 141.72 126.6 126.6 111.74
Capital WIP 40.6 32.49 5.89 5.89 10.96
Intangible WIP 0 0 0 0 0
Investments 0 0 0 0 0
Loans & Advances 801.72 885.23 102.06 939.09 105.68
Other N/C Assets 2.6 2.25 1.9 1.9 4.37
Current Assets 983.87 1171.28 524.22 930.61 526.39
Total Assets 1937.85 2232.97 760.67 2004.09 759.14
* Other Non-current Liabilities include Net deferred Liabilities

Cash Flows (All Figures are in Crores.)

PARTICULARS Jun 2022 Jun 2023 Mar 2024 Jun 2024 Mar 2025
Profit from operations 253.37 314.2 273.32 273.32 311.62
Adjustment 27.31 41.49 52.27 52.27 12.2
Changes in Assets & Liabilities -47.3 -30.02 -12.12 -12.12 -73.81
Tax Paid -63.86 -89.66 -85.18 -85.18 -81.32
Operating Cash Flow 169.52 236.01 228.29 228.29 168.69
Investing Cash Flow -25.54 -21.5 -6.87 -6.87 9.59
Financing Cash Flow -288.63 -98.47 -418.11 -418.11 -234.74
Net Cash Flow -144.65 116.04 -196.69 -196.69 -56.46

Corporate Actions

Investors Details

PARTICULARS Jun 2024% Sep 2024% Dec 2024% Mar 2025% Jun 2025%
promoters 51.82 51.82 51.82 51.82 51.82
procter and gamble overse... 51.82 51.82 51.82 51.82 51.82
PARTICULARS Jun 2024% Sep 2024% Dec 2024% Mar 2025% Jun 2025%
investors 48.18 48.18 48.18 48.18 48.18
icici prudential equity &... - - - - 2.79
investor education and pr... - - - - 0.37
life insurance corporatio... 2.45 - 2.19 2.03 1.91
nippon life india trustee... 3.98 4.10 4.10 4.10 4.17
uti- mnc fundd - - - - 1.95
icici prudential smallcap... - - 2.77 2.78 -
investor education and pr... 0.36 0.36 0.38 0.38 -
uti-mnc fund - 1.89 1.89 1.90 -
icici prudential mnc fund... - 2.61 - - -
lici asm non par - 2.49 - - -
icici prudential s&p bse ... 2.60 - - - -
uti - healthcare fund 1.87 - - - -

Annual Reports

Title Link
Title Link
Annual Report 2024
Annual Report 2023
Annual Report 2022
Annual Report 2021
Annual Report 2020
Annual Report 2018
Annual Report 2017
Annual Report 2017

Ratings & Research Reports

TYPE AGENCY Link
TYPE AGENCY Link
Credit ICRA
TYPE AGENCY Link
TYPE AGENCY Link
 No Research reports exist for this company.Report us

Concalls & Presentations

TYPE QUARTER Link
TYPE QUARTER Link
 Currently we do not have any Concall related to this company.Report us
TYPE QUARTER Link
TYPE QUARTER Link
Presentation Q2FY20

Company News

Procter & Gamble Health re-submits annual report 26 Aug, 9:45 AM Procter & Gamble Health informs about annual report 6 Aug, 5:13 PM Procter & Gamble Health informs about BRSR 6 Aug, 4:22 PM Procter&Gamble Healt - Quaterly Results 1 Aug, 2:03 PM Procter&Gamble Healt - Quaterly Results 1 Aug, 2:03 PM Procter&Gamble Healt - Quaterly Results 1 Aug, 2:03 PM Procter & Gamble Health informs about outcome of analyst meeting 17 Jun, 1:11 PM Procter & Gamble Health informs about change in senior management personnel 11 Jun, 12:27 PM Procter & Gamble Health informs about updates 9 Jun, 2:12 PM Procter&Gamble Healt - Quaterly Results 29 May, 5:49 PM Procter&Gamble Healt - Quaterly Results 29 May, 5:49 PM Procter&Gamble Healt - Quaterly Results 29 May, 5:49 PM Procter & Gamble Health informs about postal ballot notice 10 Mar, 11:55 AM Procter & Gamble Health informs about integrated filing 18 Feb, 4:59 PM Procter & Gamble Health reports 26% rise in December quarter 12 Feb, 6:37 PM Procter&Gamble Healt - Quaterly Results 12 Feb, 2:47 PM Procter&Gamble Healt - Quaterly Results 12 Feb, 2:47 PM Procter&Gamble Healt - Quaterly Results 12 Feb, 2:47 PM Procter & Gamble Health informs about loss of share certificates 21 Dec, 11:40 AM Procter & Gamble Health informs about change in senior management personnel 7 Dec, 12:38 PM Procter&Gamble Healt - Quaterly Results 4 Nov, 5:52 PM Procter&Gamble Healt - Quaterly Results 4 Nov, 5:52 PM Procter&Gamble Healt - Quaterly Results 4 Nov, 5:52 PM Procter & Gamble Health informs about loss of share certificates 9 Oct, 12:17 PM Procter & Gamble Health informs about certificate 9 Oct, 12:15 PM Procter&Gamble Healt - Quaterly Results 21 Aug, 4:05 PM Procter&Gamble Healt - Quaterly Results 21 Aug, 4:05 PM Procter&Gamble Healt - Quaterly Results 21 Aug, 4:05 PM Procter&Gamble Healt - Quaterly Results 2 May, 8:01 PM Procter&Gamble Healt - Quaterly Results 2 May, 8:01 PM Procter & Gamble Hygiene and Health Care informs about disclosure 27 Mar, 10:08 AM Procter & Gamble Health informs about loss of share certificates 4 Mar, 11:13 AM Procter & Gamble Health informs about corporate action 6 Feb, 5:29 PM Procter&Gamble Healt - Quaterly Results 6 Feb, 4:44 PM Procter&Gamble Healt - Quaterly Results 6 Feb, 4:44 PM Procter&Gamble Healt - Quaterly Results 6 Feb, 4:44 PM Procter & Gamble Health informs about loss of share certificates 20 Jan, 1:13 PM Procter & Gamble Health informs about loss of share certificate 21 Dec, 4:39 PM Procter & Gamble Health informs about loss of share certificate 18 Dec, 12:17 PM Procter&Gamble Healt - Quaterly Results 3 Nov, 7:54 PM Procter&Gamble Healt - Quaterly Results 3 Nov, 7:54 PM Procter & Gamble Hygiene & Health Care informs about outcome of board meeting 30 Oct, 5:25 PM Procter & Gamble Health informs about loss of share certificates 21 Oct, 10:34 AM Procter & Gamble Health informs about disclosure 27 Sep, 12:35 PM Procter & Gamble Health to discontinue production of injections at Goa plant 27 Sep, 10:50 AM Procter&Gamble Healt - Quaterly Results 23 Aug, 8:31 PM Procter&Gamble Healt - Quaterly Results 23 Aug, 8:31 PM Procter & Gamble Health informs about issuance of duplicate share certificate 27 Jul, 9:02 AM Procter & Gamble Health reports 16% rise in Q3 net profit 16 May, 11:13 AM Procter&Gamble Healt - Quaterly Results 15 May, 8:16 PM

Procter&Gamble Healt Stock Price Analysis and Quick Research Report. Is Procter&Gamble Healt an attractive stock to invest in?

Stock investing requires careful analysis of financial data to determine a company's true net worth. This is generally done by examining the company's profit and loss account, balance sheet and cash flow statement, which can be time-consuming and cumbersome.

Examining a company's financial ratios is an easier way to determine its performance, which can help to make sense of the overwhelming amount of information in its financial statements. 

Here are a few indispensable ratios that should be a part of every investor’s research process, or, in simpler words, how to analyse Procter&Gamble Healt. 

  • PE ratio: Price to Earnings ratio, which indicates how much an investor is willing to pay for a share for every rupee of earnings. A general rule of thumb is that shares trading at a low P/E are undervalued (it depends on other factors too). Procter&Gamble Healt has a PE ratio of 34.4782646391117 which is high and comparatively overvalued.

  • Return on Assets (ROA): Return on Assets measures how effectively a company can earn a return on its investment in assets. In other words, ROA shows how efficiently a company can convert the money used to purchase assets into net income or profits. Procter&Gamble Healt has ROA of 16.9664% which is a good sign for future performance. (Higher values are always desirable.)

  • Current ratio: The current ratio measures a company's ability to pay its short-term liabilities with its short-term assets. A higher current ratio is desirable so that the company could be stable to unexpected bumps in business and economy. Procter&Gamble Healt has a Current ratio of 2.4448.

  • Return on equity: ROE measures the ability of a firm to generate profits from its shareholders' investments in the company. In other words, the return on equity ratio shows how much profit each rupee of common stockholders’ equity generates. Procter&Gamble Healt has a ROE of 44.1542%. (Higher is better)

  • Debt to equity ratio: It is a good metric to check out the capital structure along with its performance. Procter&Gamble Healt has a Debt to Equity ratio of 0 which means that the company has low proportion of debt in its capital.

  • Sales growth: Procter&Gamble Healt has reported revenue growth of -18.8567% which is poor in relation to its growth and performance. 

  • Operating Margin: This will tell you about the operational efficiency of the company. The operating margin of Procter&Gamble Healt for the current financial year is 34.0826616140531%.

  • Dividend Yield: It tells us how much dividend we will receive in relation to the price of the stock. The current year dividend for Procter&Gamble Healt is Rs 125 and the yield is 1.998%.

  • Earnings Per Share: It tells us how much profit is allocated to to each outstanding share of a common stock. The latest EPS of Procter&Gamble Healt is Rs 181.0851. The higher the EPS, the better it is for investors. 

One can find all the Financial Ratios of Procter&Gamble Healt in Ticker for free. Also, one can get the intrinsic value of Procter&Gamble Healt by using Valuation Calculators, which are available with a Finology ONE subscription. 

Procter&Gamble Healt FAQs

Q1. What is Procter&Gamble Healt share price today?
Ans: The current share price of Procter&Gamble Healt is Rs 6243.5.

Q2. What is the market capitalisation of Procter&Gamble Healt?
Ans: Procter&Gamble Healt has a market capitalisation of Rs 10363.8241517 Cr., calculated based on its latest share price.

Q3. What are the P/E and P/B ratios of Procter&Gamble Healt?
Ans: The PE ratio of Procter&Gamble Healt is 34.4782646391117 and the P/B ratio of Procter&Gamble Healt is 17.3235857699929, showing how the stock is valued against its earnings and book value.

Q4. What is the 52-week high and low of Procter&Gamble Healt share?
Ans: The 52-week high share price of Procter&Gamble Healt is Rs 6739, and the 52-week low share price of Procter&Gamble Healt is Rs 4863.

Q5. Does Procter&Gamble Healt pay dividends?
Ans: Currently, Procter&Gamble Healt pays dividends. Dividend yield of Procter&Gamble Healt is around 1.998%.

Q6. What are the face value and book value of Procter&Gamble Healt shares?
Ans: The face value of Procter&Gamble Healt shares is Rs 10, while the book value per share of Procter&Gamble Healt is around Rs 360.4046. Face value is the nominal value set by the company, whereas book value reflects its accounting worth.

Q7. What is the debt of Procter&Gamble Healt?
Ans: Procter&Gamble Healt has a total debt of Rs 0 Cr., which affects investor sentiment and financial stability. 

Q8. What are the ROE and ROCE of Procter&Gamble Healt?
Ans: The ROE of Procter&Gamble Healt is 44.1542% and ROCE of Procter&Gamble Healt is 58.045%. ROE shows how efficiently the company is generating profit from shareholders’ equity, while the ROCE is reflects how efficiently the company uses its capital to generate returns.

Q9. Is Procter&Gamble Healt a good buy for the long term?
Ans: The Procter&Gamble Healt long-term outlook depends on debt levels, earnings growth, and sector trends. If it sustains profits and manages debt well, it may be considered for long-term investment.

Q10. Is Procter&Gamble Healt undervalued or overvalued?
Ans: Based on valuation ratios like P/E, P/B, and EV/EBITDA, one can analyse whether the Procter&Gamble Healt appears undervalued or overvalued at current levels. You can check detailed valuation metrics and peer comparisons on Finology Ticker.

Q11. How to check Procter&Gamble Healt’s financials?
Ans: You can review Procter&Gamble Healt’s financial statements - including balance sheet, income statement, and quarterly results - on Finology Ticker.

Last Updated on:
Brief about Procter&Gamble Healt

Procter & Gamble Health Ltd. Financials: Check Share price, Balance Sheet, Annual report, and Quarterly Results for company analysis

Procter & Gamble Health Ltd. stock analysis page is a comprehensive resource for long-term investors searching for accurate information about the company. Our website provides investors with the necessary tools and resources, including share price, balance sheet, annual report, dividend, quarterly result, stock price, price chart, news, concall, transcripts, investor presentations, promoters, and shareholders analysis. These tools enable investors to make informed investment decisions that ensure long-term growth.

Procter & Gamble Health Ltd. Share Price Analysis:

Procter & Gamble Health Ltd.'s share price is a key indicator of the company's financial performance. As a potential investor, it's crucial to analyze the share price's trends and performance over time. Ticker stock analysis page provides investors with historical share price charts that track the company's performance over an extended period. This feature allows investors to monitor the stock's performance and identify trends that may impact future growth. Ticker's pre-built screening tools can assist investors in comparing Procter & Gamble Health Ltd.'s share price performance with its peers, enabling them to make informed investment decisions. A stock's share price is determined by a range of factors such as market sentiment, financial performance, and general economic conditions. 

Procter & Gamble Health Ltd. Balance Sheet Analysis:

Analyzing Procter & Gamble Health Ltd.'s balance sheet is an essential factor for investors interested in understanding the company's financial stability and health. The balance sheet's information provides important insights into the company's assets, liabilities, and shareholders' equity. Ticker provides access to Procter & Gamble Health Ltd.'s balance sheet as a downloadable document, which investors can use to perform an in-depth analysis. In addition, our pre-built screening tools can assist investors in analyzing the company's financial health and evaluating its long-term growth potential.

Procter & Gamble Health Ltd. Annual Report Analysis:

Procter & Gamble Health Ltd.'s annual report is a vital resource for investors interested in long-term investments. The report offers information on the company's strategic initiatives, future goals, and financial performance. Ticker offers investors access to the company's annual report as a downloadable document that they can use to perform an in-depth analysis. Our pre-built screening tools can also provide insights into the company's performance, making it easier for investors to make informed investment decisions.

Procter & Gamble Health Ltd. Dividend Analysis:

Investors interested in Procter & Gamble Health Ltd.'s stock should evaluate the company's dividend payout policies. The company's dividend payout trends are a crucial factor when assessing the stock's potential for long-term growth. Ticker features information on the company's dividend payout history, providing investors with valuable insights into the company's potential as a long-term investment option.

Procter & Gamble Health Ltd. Quarterly Results Analysis:

Procter & Gamble Health Ltd.'s quarterly results offer insights into the company's financial performance, including revenue, profit, and loss. Investors can use this information to assess the company's growth potential. Tickder features a downloadable copy of Procter & Gamble Health Ltd.'s quarterly results, which investors can use to make informed investment decisions. Our pre-built screening tools provide insights into the company's financial performance compared to its peers, allowing investors to evaluate its long-term growth potential.

Procter & Gamble Health Ltd. Stock Price Analysis:

Monitoring Procter & Gamble Health Ltd.'s stock prices regularly is crucial when assessing the company's financial performance. Our stock analysis page features current stock price updates, enabling investors to track market trends and identify potential investment opportunities. Ticker's pre-built screening tools can also help investors analyze the company's stock price performance compared to its peers, making it easier to make informed investment decisions. Our website provides pre-built screening tools to help investors analyze stock price and performance.

Procter & Gamble Health Ltd. Price Chart Analysis:

A visual representation of Procter & Gamble Health Ltd.'s share price trends over time is a valuable tool for long-term investors. The price chart allows investors to analyze the company's share price performance and identify any trends that could impact future growth. Our website provides investors with a price chart they can use for an in-depth analysis. Our pre-built screening tools can also assist investors in evaluating the company's long-term growth potential by analyzing its performance compared to its peers.

Procter & Gamble Health Ltd. News Analysis:

Keeping up with the latest news and developments that impact Procter & Gamble Health Ltd.'s stock is crucial for investors. Our website offers timely news articles related to the company, providing investors with up-to-date insights into its performance. The news section of our website features reliable information on significant events, regulatory changes, and other factors that could potentially impact the stock's performance. Ticker's pre-built screening tools can also provide investors with information about the company's global and local news.

Procter & Gamble Health Ltd. Concall Transcripts Analysis:

Procter & Gamble Health Ltd.'s concall transcripts offer investors insights into the company's future guidance and outlook. Our website provides access to these critical documents, enabling long-term investors to stay informed about the company's financial health and future growth. Our pre-built screening tools can also help investors perform an in-depth analysis of the information presented in the transcripts.

Procter & Gamble Health Ltd. Investor Presentations Analysis:

Procter & Gamble Health Ltd. prepares investor presentations to offer investors detailed information on the company's operations and financial performance. These presentations are valuable resources for long-term investors to study the company's strategic initiatives, providing necessary insights that could potentially impact the stock's value. Our website offers access to these presentations as downloadable documents that investors can use for an in-depth analysis. Our premium feature tools can also assist investors in performing a comprehensive analysis of the presented data.

Procter & Gamble Health Ltd. Promoters and Shareholders Analysis:

Understanding Procter & Gamble Health Ltd.'s promoters and shareholders is essential when assessing the viability of investing in its stock. Our stock analysis page provides vital information regarding the company's promoters and other shareholders. Long-term investors must consider these elements before making any investment decisions. Our pre-built screening tools can assist investors in analyzing the company's shareholding patterns and evaluating its growth potential.   

Procter & Gamble Health Balance Sheet Analysis

Procter & Gamble Health's Equity and Liabilities

Over the years from June 2020 to June 2024, Procter & Gamble Health's total liabilities saw fluctuations, starting at Rs 2,112.12 Cr in June 2020, dipping to Rs 1,937.85 Cr in June 2022, and climbing back to Rs 2,004.09 Cr by June 2024. The share capital remained steady at Rs 16.60 Cr throughout the period, while total reserves decreased from Rs 889.74 Cr in 2020 to Rs 521.64 Cr in 2024, indicating potential reinvestment or distribution decisions.

Procter & Gamble Health's Debt Status

Procter & Gamble Health maintained a debt-free status from June 2020 to June 2024, with borrowings consistently reported at Rs 0 Cr. This indicates strong financial management and a conservative approach towards leverage.

Procter & Gamble Health's Asset Management

Total assets of Procter & Gamble Health matched its liabilities each year, maintaining balance sheet integrity. Notably, the net block component of assets increased from Rs 97.92 Cr in 2020 to Rs 126.60 Cr in 2024, reflecting ongoing investments in physical assets. However, an interesting shift was observed in current assets, which decreased from Rs 1,264.84 Cr in 2020 to Rs 930.61 Cr in 2024.

This data is an analysis for the Standalone Balance Sheet of Procter & Gamble Health.

For investors analyzing stocks, understanding the asset management and financial stability as indicated by the balance sheet components can provide valuable insights into the company’s standing in the market and its sectors.

Read More
X